Comparative Pharmacology
Head-to-head clinical analysis: TRIAZOLAM versus ZAXOPAM.
Peer-Reviewed Evidence
Head-to-head clinical analysis: TRIAZOLAM versus ZAXOPAM.
TRIAZOLAM vs ZAXOPAM
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Triazolam is a benzodiazepine that binds to GABA-A receptors at the alpha-1 subunit, potentiating the inhibitory effects of GABA and increasing chloride ion influx, leading to neuronal hyperpolarization and sedation.
Zaxopam is a benzodiazepine that enhances GABA-A receptor activity by binding to the benzodiazepine site, increasing chloride ion influx and causing neuronal hyperpolarization.
0.125-0.25 mg orally once daily at bedtime; maximum 0.5 mg/day.
10 mg orally twice daily, titrated to a maximum of 30 mg twice daily based on response and tolerability; oral route.
None Documented
None Documented
1.5-5.5 hours (mean 2-4 hours) in healthy adults; prolonged in hepatic cirrhosis and elderly.
Clinical Note
moderateTriazolam + Fluticasone propionate
"The risk or severity of adverse effects can be increased when Triazolam is combined with Fluticasone propionate."
Clinical Note
moderateTriazolam + Sulfisoxazole
"The metabolism of Sulfisoxazole can be decreased when combined with Triazolam."
Clinical Note
moderateTriazolam + Erythromycin
"The serum concentration of Erythromycin can be increased when it is combined with Triazolam."
Clinical Note
moderateTriazolam + Cyclosporine
Terminal elimination half-life is 12-15 hours, allowing for once-daily dosing in most patients.
Primarily renal: approximately 80% as metabolites, less than 2% unchanged; biliary/fecal: minor (about 8-10%).
Renal excretion accounts for approximately 80% of the administered dose, predominantly as conjugated metabolites; biliary/fecal excretion accounts for the remaining 20%.
Category D/X
Category C
Benzodiazepine
Benzodiazepine
"The metabolism of Cyclosporine can be decreased when combined with Triazolam."